Tirzepatide vs SNAP-8
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
TirzepatideSkin & Cosmetic
SNAP-8- Summary
- Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that produces greater weight loss than semaglutide in head-to-head trials. SURMOUNT-1 trial showed average 21% body weight reduction at 72 weeks at the highest dose. Marketed as Mounjaro (diabetes) and Zepbound (obesity).
- SNAP-8 is a synthetic octapeptide cosmetic ingredient that reduces the depth of expression lines and wrinkles by competitively inhibiting the SNARE complex involved in acetylcholine release at neuromuscular junctions, providing a topical 'Botox-like' effect.
- Half-Life
- ~5 days
- N/A — topical application; local effect duration depends on formulation
- Admin Route
- SubQ
- Topical
- Research
- —
- —
- Typical Dose
- 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
- 3–10% concentration in formulation
- Frequency
- Once weekly, subcutaneous
- 1–2x daily
- Key Benefits
- Average 21% body weight reduction at highest dose (SURMOUNT-1)
- Superior to semaglutide in head-to-head SURPASS trials
- Dual GIP/GLP-1 mechanism for enhanced metabolic control
- Significant reduction in HbA1c for type 2 diabetes
- Improved cardiovascular risk markers
- Reduces visceral fat preferentially
- FDA-approved for T2DM (Mounjaro) and obesity (Zepbound)
- Weekly dosing
- Reduces depth of dynamic expression wrinkles
- Smooths forehead lines, crow's feet, glabellar lines
- Non-invasive topical Botox alternative
- Can be incorporated into serums, creams, eye contour products
- Reduces muscle contraction without paralysis
- Improves skin texture and firmness over time
- Complements other anti-aging peptides (Argireline, Matrixyl)
- Side Effects
- Nausea (most common during titration)
- Vomiting
- Diarrhea or constipation
- Abdominal pain
- +3 more
- Generally excellent tolerability
- Rare: mild redness in sensitive individuals
- Not suitable for injection (topical use only)
- Stacks With
- —
- —